How does difelikefalin actually stop the itching that dialysis causes?
Difelikefalin is a kappa opioid agonist—a medication that activates special itch-blocking receptors in your spinal cord and brain. When you get the injection during dialysis, it tells your nervous system to turn down the itch signal by roughly 50% in most patients [1].
In the Phase 3 trial published in The New England Journal of Medicine, 50% of hemodialysis patients with moderate-to-severe pruritus experienced a drop of 4 or more points on the itch severity scale (0–10 range). Itch relief appeared within 2–4 weeks of starting three-times-weekly dosing [1].
Your kidneys normally filter out uremic toxins—waste products that build up and trigger itching. When kidneys fail, these toxins accumulate in your skin and nerves, creating a constant itch signal. Difelikefalin works by activating kappa receptors on nerve cells, which essentially dampens that itch message before it reaches your brain [1][2].
Real-world trade-offs: You need the injection three times per week during your regular dialysis session—no extra office visits. Some patients feel mild dizziness or a small drop in blood pressure in the first 1–2 doses, but this usually settles. If you see no improvement by week 6, your nephrologist will likely recommend stopping [1][3].
Ask your nephrologist to check your blood pressure and heart rate before your first dose. If you feel dizzy or lightheaded during the first injection, let the dialysis nurse know immediately—they can slow the infusion or give you fluids [9].